Clinical Trial

A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this Phase 1 study is to understand and compare the amount of EDG-7500 in the blood after a single dose in participants with different levels of liver function impairment versus participants with normal liver function. The safety of EDG-7500 in adult participants with different levels of liver function impairment will also be evaluated in this study.
Protocol Amendment History 2 changes
critical Trial completed 2026-08-01
notable Enrollment reduced: 32 -> 25 participants 2026-08-01
Trial Details
NCT Number NCT07324616
Lead Sponsor Edgewise Therapeutics, Inc.
Conditions Hepatic Impairment (HI)
Enrollment 25 participants
Start Date 2026-01-26
Primary Completion 2026-04-07 (estimated)
Study Completion 2026-04-07 (estimated)
Updated on ClinicalTrials.gov 2026-07-31